Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

J & J Seeks to Arbitrate Schering Remicade Deal

By Pharmaceutical Processing | May 21, 2009

NEW YORK (AP) — Johnson & Johnson has notified Merck & Co. that it plans to seek arbitration on whether it can pull out of a blockbuster drug partnership with Schering-Plough Corp. as that company sells itself to Merck for $41.1 billion. Merck said in a filing Wednesday with the Securities and Exchange Commission that Johnson & Johnson told the company of the move May 5. At stake in arbitration is about $2 billion a year in revenue to the newly combined company from the arthritis drug Remicade, whose sales J&J and Schering-Plough split. Merck and Schering-Plough have structured their deal as a reverse merger, allowing Schering-Plough to remain as the surviving entity. That’s intended to avoid triggering terms in J&J’s deal with Schering-Plough that allow it to pull out of the Remicade venture and take all its revenue if control of Schering changes hands. Johnson & Johnson made clear in an e-mailed statement that it wants back the full rights to Remicade and another drug made by its Centocor Ortho Biotech subsidiary because of the acquisition deal. “As its public statements make clear, Merck is acquiring Schering-Plough,” the statement said. “The acquisition constitutes a change of control and triggers Centocor’s right to terminate.” Under the existing deal, Schering-Plough has rights to sell the drug overseas. The joint venture also includes the arthritis drug golimumab, approved by the Food and Drug Administration in April. The move by Johnson & Johnson isn’t surprising, said Steve Brozak of WBB Securities. “We know J&J wants something, and we know that Merck and Schering-Plough are going to defend,” he said. “The question is what will be the ultimate agreement.” Analysts have previously warned that the buyout could be thrown into upheaval if New Brunswick, N.J.-based J&J ends up with full rights to Remicade, which would in turn lower the value of Schering-Plough. Merck says it still expects its acquisition of Schering-Plough to close by the end of the year.

Related Articles Read More >

A Zipline fixed-wing drone in the air drops a package
Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
Pfizer logo
Pfizer to spend $120M to make COVID-19 oral treatment in U.S.
Image of MedTrace Pharma's P3 automated delivery system for 15-O water in action
MedTrace Pharma moves forward on 15 O-water imaging tech
coronavirus COVID-19 Pfizer
NIH starts evaluating second COVID-19 booster shots in adults

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards